Decoy Therapeutics (DCOY) Return on Capital Employed (2015 - 2026)

Decoy Therapeutics (DCOY) posted quarterly Return on Capital Employed of 253.73% for Q1 2026, up 31.43% quarter-over-quarter from 370.0% in Q4 2025.

Decoy Therapeutics (DCOY) Return on Capital Employed (2015 - 2026) Analysis & Trends

Decoy Therapeutics (DCOY) has reported Return on Capital Employed for 8 consecutive years, with 253.73% the latest figure, recorded in Q1 2026.

In Q1 2026, Return on Capital Employed changed N/A year-over-year to 253.73%; the TTM figure through Mar 2026 stood at 253.73% (changed N/A YoY), while the FY2025 annual figure was 673.79%, down 49967.0% from the prior year.
Return on Capital Employed climbed to 253.73% in Q1 2026 per DCOY's latest filing, from 370.0% in the prior quarter.
Across five years, Return on Capital Employed topped out at 253.73% in Q1 2026 and bottomed at 370.0% in Q4 2025.
Historically, Return on Capital Employed has averaged 306.96% across 3 years, with a median of 297.15% in 2024.
On a YoY basis, Return on Capital Employed climbed as much as 7286 bps in 2025 and fell as far as 7286 bps in 2025.
Decoy Therapeutics' Return on Capital Employed stood at 297.15% in 2024, then dropped by 25 bps to 370.0% in 2025, then surged by 31 bps to 253.73% in 2026.
Business Quant data shows DCOY's Return on Capital Employed at 253.73% in Q1 2026, 370.0% in Q4 2025, and 297.15% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn	10.74%
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn	-
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn	-38.20%
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	13.68%
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn	26.09%
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn	-6.85%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-50.93%
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	7.88%
10	Decoy Therapeutics	1.82 Mn	1.82 Mn	-	-368.17%

Download Data